Monoclonal antibody therapy for hairy cell leukemia.
The use of MoAb therapy for the treatment of HCL offers great promise and potential for improving progression-free survival. Rituximab has activity in the setting of previously treated HCL and the ability to eradicate MRD after 2-CdA given as frontline therapy. Alemtuzumab, epratuzumab, Hu-Max-CD20, and other candidate MoAb's should be studied in HCL. Appropriate pharmacologic investigation, use of antigen modulation, and assessments of soluble antigen levels should be considered with future clinical trial s of MoAb's in HCL to optimize therapeutic strategies.
Thomas
Deborah A
DA
Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, 77030, USA. debthomas@mdanderson.org
Ravandi
Farhad
F
Kantarjian
Hagop
H
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000652:urine*; D018951:Antigens, CD20 / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy* / Q000276:immunology; D018365:Neoplasm, Residual
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents